http://www.tphase.com/about_us/media_events/ en-us Tue, 12 Feb 2013 04:00:00 EST info@tphase.com http://www.tphase.com/about_us/media_events/?id=36 Watertown, MA – February 12, 2013 – Tetraphase Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering. Barclays and BMO Capital Markets are acting as joint book-running managers. Stifel, JMP Securities and Needham & Company are acting as co-managers for the offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847, or by emailing barclaysprospectus@broadridge.com. A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement ... Tue, 12 Feb 2013 04:00:00 EST http://www.tphase.com/about_us/media_events/?id=36 http://www.tphase.com/about_us/media_events/?id=35 Watertown, MA – September 13, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that Tetraphase President & Chief Executive Officer Guy Macdonald is scheduled to present at the following conferences in September and October: • The annual UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 3:00 p.m. Eastern time at The Grand Hyatt, New York, New York • BioPharm America™ 2012 on Friday, September 21, 2012 at 8:45 a.m. Eastern time at The Westin Boston Waterfront Hotel, Boston, Massachusetts • The 11th Annual BIO Investor Forum, which will be held from October 9-10, 2012 at The Palace Hotel, San Francisco, California About Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals is a clinical stage bioph... Thu, 13 Sep 2012 09:18:00 EST http://www.tphase.com/about_us/media_events/?id=35 http://www.tphase.com/about_us/media_events/?id=34 – Eravacycline cure rates compare favorably to ertapenem in the clinical treatment of cIAIs– – In the trial, eravacycline was well tolerated with low rates of gastrointestinal side effects– –Results support continued development of eravacycline for the treatment of serious infections caused by drug-resistant gram-negative pathogens– San Francisco, CA – September 12, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The results of the study show that eravacycline was highly active against drug-resistant bacterial pathogens, demonstrating infection cure rates similar to that of ertapenem (the comparator drug u... Wed, 12 Sep 2012 09:53:00 EST http://www.tphase.com/about_us/media_events/?id=34 http://www.tphase.com/about_us/media_events/?id=33 – Presentations Include Phase 2 Data on Lead Agent Eravacycline (TP-434) as well as Laboratory Evaluations of TP-271 and Novel 8-Heterocycle Substituted Tetracyclines– Watertown, MA – September 5, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, announced today that results of new research on several of its next-generation tetracycline antibiotics will be presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The presentations will include late-breaking results of a Phase 2 clinical trial of the company’s lead agent, eravacycline (TP-434), and chemical and biological evaluations of other novel tetracyclines in the company’s portfolio. ICAAC will be held September 9-12, 2012, in San Francisco, CA. “We are very excited about the presentation of results from our Phase 2 clinical study of intravenous... Wed, 05 Sep 2012 11:39:00 EST http://www.tphase.com/about_us/media_events/?id=33 http://www.tphase.com/about_us/media_events/?id=32 Watertown, MA – August 30, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that Tetraphase President & Chief Executive Officer Guy Macdonald will present at the Stifel Nicolaus 2012 Healthcare Conference on Wednesday, September 5, 2012, at 3:50 p.m. Eastern time. The conference will take place at The Four Seasons Hotel in Boston, Massachusetts. About Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant and gram-negative infections. The company has developed an emerging pipeline of potent nov... Thu, 30 Aug 2012 09:25:00 EST http://www.tphase.com/about_us/media_events/?id=32 http://www.tphase.com/about_us/media_events/?id=31 Watertown, MA – July 9, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that the company’s executives will present at The JMP Securities Healthcare Conference. Tetraphase President and Chief Executive Officer Guy Macdonald and Tetraphase Chief Medical Officer Patrick Horn, M.D., Ph.D. are scheduled to speak at 10:30 a.m. (ET) on Friday, July 13, 2012. The Conference will take place at The Peninsula Hotel New York in New York City. About Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant ... Mon, 09 Jul 2012 09:38:00 EST http://www.tphase.com/about_us/media_events/?id=31 http://www.tphase.com/about_us/media_events/?id=30 – Data Highlight Enhanced Potency and Favorable Pharmacokinetics of New Agents Against Pseudomonas and Gram-Negative Respiratory Pathogens– Watertown, MA - April 2, 2011 - Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs. These data, which focus on significant gram-negative pathogens – including Pseudomonas aeruginosa, and troublesome gram-positive respiratory pathogens – were described in seven poster presentations at the 22nd European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in London, UK. "These are the first reports of novel tetracyclines with improved potency and efficacy against contemporary P. aeruginosa isolates," said Guy Macdonald, President and Chief Executive Officer... Mon, 02 Apr 2012 03:45:00 EST http://www.tphase.com/about_us/media_events/?id=30 http://www.tphase.com/about_us/media_events/?id=29 Watertown, MA – March 29, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that the Company will present at the 11th Annual Needham Healthcare Conference. Tetraphase President and CEO Guy Macdonald will present for the company at 11:00 a.m. (ET) on Wednesday, April 4, 2012. The Conference will take place at The New York Palace Hotel in New York, New York. About Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant and gram-negative infections. The company has developed an emerging pipeline of pote... Thu, 29 Mar 2012 10:10:00 EST http://www.tphase.com/about_us/media_events/?id=29 http://www.tphase.com/about_us/media_events/?id=28 Watertown, MA – March 1, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens), today announced that the Company will present at the Cowen and Company 32nd Annual Health Care Conference. Tetraphase President and CEO Guy Macdonald will present for the company at 4:00 p.m. (ET) on Tuesday, March 6, 2012. The Conference will take place at The Boston Marriott Copley Place in Boston, Massachusetts. About Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant and gram-negative infections. The company has developed an emerging... Thu, 01 Mar 2012 10:03:00 EST http://www.tphase.com/about_us/media_events/?id=28 http://www.tphase.com/about_us/media_events/?id=27 Watertown, MA – February 16, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $67 million for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens and the lead product candidate in Tetraphase's clinical pipeline. Tetraphase will be working on this contract with Buffalo, NY-based CUBRC, Inc. “BARDA’s award covering the development of TP-434 brings the total federal funding in support of the development of Tetraphase’s antibiotics to more than $100 million,” said Guy Macdonald, president and chief executive officer of Tetraphase. “Tetraphase and CUBRC are proud... Wed, 01 Feb 2012 11:27:00 EST http://www.tphase.com/about_us/media_events/?id=27 http://www.tphase.com/about_us/media_events/?id=26 – Biopharmaceutical Industry Veteran to Help Advance Strategic Value of Tetraphase’s Promising Portfolio of Potent New Antibiotics –  Watertown, MA – January 5, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics, today announced that L. Patrick “Pat” Gage, Ph.D., biopharmaceutical industry pioneer, has been appointed as the company’s Chairman of the Board. In this role, Dr. Gage will provide strategic leadership to the Tetraphase board of directors and work with the management team as the company advances its novel antibiotic drug candidates, which are designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens. “I am excited to work with the Tetraphase team as its innovative chemistry platform and robust antibiotics portfolio continues to advance," said Dr. Gage. “With... Thu, 05 Jan 2012 09:40:00 EST http://www.tphase.com/about_us/media_events/?id=26 http://www.tphase.com/about_us/media_events/?id=25 Watertown, MA – October 20, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that executives from the company are scheduled to present at the following conferences in October and November: • The 10th Annual BIO Investor Forum on October 25-26, 2011, at The Palace Hotel, San Francisco, California • GTC’s 8th Anti-Infectives Partnering and Deal-Making Conference on November 7-8, 2011, The Omni Parker House in Boston, Massachusetts • Lazard Capital Markets 8th Annual Healthcare Conference on November 15-16, 2011, at the Pierre Hotel, New York, New York • The 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference on November 14-18, 2011, at the Mirage Hotel, Las Vegas, Nevada About Tetraphase Phar... Thu, 20 Oct 2011 01:35:00 EST http://www.tphase.com/about_us/media_events/?id=25 http://www.tphase.com/about_us/media_events/?id=24 Watertown, MA  October 19, 2011  Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that National Institutes of Healths (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has awarded a contract worth up to $36 million for the development of TP-271, Tetraphases novel antibiotic for respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens. Tetraphase will be working on this contract as a sub-contractor to Buffalo, NY-based CUBRC, Inc. We are pleased that NIAID has granted an award to support the development of TP-271, which will be the fourth compound to enter development from our novel chemistry platform, said Guy Macdonald, president and chief executive officer of Tetraphase. Tetraphase and CUBRC share NI... Wed, 19 Oct 2011 11:13:00 EST http://www.tphase.com/about_us/media_events/?id=24 http://www.tphase.com/about_us/media_events/?id=23 Watertown, MA – September 15, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that President and CEO Guy Macdonald will present a corporate update at the following investor conferences in New York, New York: • UBS Global Life Sciences Conference on September 19, 2011, at 12:00 p.m. Eastern time at The Grand Hyatt Hotel • JMP Securities Healthcare Conference on September 27, 2011, at 2:30 p.m. Eastern time at The St. Regis Hotel About Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug-resistant ... Thu, 15 Sep 2011 10:02:00 EST http://www.tphase.com/about_us/media_events/?id=23 http://www.tphase.com/about_us/media_events/?id=22 – Seven Posters and a Presentation to Highlight Activity Against Multidrug-Resistant (MDR) Pathogens and Complicated Infections – Watertown, MA – September 13, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that data describing the company’s ongoing discovery and development work will be highlighted in seven posters and a symposium presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The Conference will be held in Chicago, IL, from September 17-20, 2011. “These new data underscore the significant potential of our proprietary antibiotic platform to produce a steady stream of new, broad-spectrum tetracycline derivatives – in intravenous and oral formulations – that are a... Tue, 13 Sep 2011 10:04:00 EST http://www.tphase.com/about_us/media_events/?id=22 http://www.tphase.com/about_us/media_events/?id=21 Watertown, MA – June 23, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the company will present at the 2011 BIO International Convention being held June 27 to 30 in Washington, DC at the Walter E. Washington Convention Center. Tetraphase President and Chief Executive Officer Guy Macdonald will participate in a panel entitled “Financing Beyond the Lead Compound: Attracting Funding for Multiproduct Platforms,” which will take place on Tuesday, June 28, from 10:00 a.m. until 11:30 a.m. About Tetraphase Pharmaceuticals Inc. Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that addre... Tue, 06 Sep 2011 03:59:00 EST http://www.tphase.com/about_us/media_events/?id=21 http://www.tphase.com/about_us/media_events/?id=20 – Presentations at the 21st ECCMID Highlight Activity of TP-434 in Both I.V. and Oral Step-Down Therapies and Potency and Oral Activity of TP-2758 Against Multidrug-Resistant Gram-Negative Pathogens – Watertown, MA - May 9, 2011 - Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous (I.V.) antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens. Tetraphase also is presenting results of pre-clinical evaluations of TP-2758, the company's second novel antibiotic, which is an oral agent for complicated urinary tract infections (cUTI). These data were described in an oral podium presentation and four poster presentations at the 21st European Congress of Clinical Microbiology an... Mon, 09 May 2011 11:08:00 EST http://www.tphase.com/about_us/media_events/?id=20 http://www.tphase.com/about_us/media_events/?id=19 – Company to Provide Insights on ‘Targeting Pathogens Resistant to Current Antibiotics’  Applauds WHO for Focus on Antimicrobial Resistance on World Health Day 2011 – Watertown, MA – April 6, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Company will present at the Cambridge Health Institute’s (CHI) 5th Annual Antibacterial Drug Development Conference “Resistance is Futile: The Challenge of Antibacterial Drug Development.” Joyce Sutcliffe, Ph.D., Tetraphase Senior Vice President, Biology, will present at 4:00 p.m. on April 12, 2011 on how Tetraphase’s drug candidates target pathogens resistant to currently used antibiotics. “At Tetraphase, our current drug candidates are designed t... Wed, 06 Apr 2011 03:05:00 EST http://www.tphase.com/about_us/media_events/?id=19 http://www.tphase.com/about_us/media_events/?id=18 Watertown, MA – March 30, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Company will present at the 10th Annual Needham Healthcare Conference. Tetraphase President and CEO Guy Macdonald will present for Tetraphase at 3:40 p.m. on Tuesday, April 5, 2011. The Conference will take place at The New York Palace Hotel in New York, New York. About Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals is a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance. Since the company’s inception in 2006, Tetraphase has developed a robust antibiotic franchise that offers the potential to dramatically... Wed, 30 Mar 2011 04:43:00 EST http://www.tphase.com/about_us/media_events/?id=18 http://www.tphase.com/about_us/media_events/?id=17 31st Annual Health Care Conference Watertown, MA – March 3, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) gram-negative pathogens) today announced that the Company will present at the Cowen and Company 31st Annual Health Care Conference. Tetraphase President and CEO Guy Macdonald will present for the company at 2:30 p.m. on Tuesday, March 8, 2011. The Conference will take place at The Boston Marriott Copley Place in Boston, Massachusetts. About Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals is a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance. Since the company’s inception in 2006, Tetraphase has developed a robust antib... Fri, 18 Mar 2011 11:15:00 EST http://www.tphase.com/about_us/media_events/?id=17 http://www.tphase.com/about_us/media_events/?id=16 Watertown, MA – February 10, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance, today announced that the Company will participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011 at the Roosevelt Hotel in New York City. Tetraphase Senior Vice President of Biology Joyce Sutcliffe, Ph.D., will participate in a panel on anti-infectives beginning at 12:15 p.m.  At 3:00 p.m., Tetraphase President and CEO Guy Macdonald will provide an overview of the Company’s strategic objectives and novel pipeline (including lead candidate TP-434, a novel broad-spectrum intravenous (I.V.) antibiotic with potential for oral stepdown). The Leerink Swann Roundtable Conference series spotlights the most promising healthcare and life sciences... Thu, 10 Feb 2011 09:37:00 EST http://www.tphase.com/about_us/media_events/?id=16 http://www.tphase.com/about_us/media_events/?id=15 - In New Role, Horn Will Direct Clinical Development of Tetraphase’s Potent Antibiotic Product Portfolio - Watertown, MA – January 24, 2011 – Tetraphase Pharmaceuticals, a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance, announced today that it has appointed Patrick Horn, M.D., Ph.D., as the company’s first Chief Medical Officer (CMO). “Patrick is a dedicated clinical pharmacologist with ten years of impressive biopharmaceutical industry experience designing and executing clinical trials for novel therapeutics,” said Guy Macdonald, President and Chief Executive Officer. “We are pleased he will drive clinical program progress for our lead antibiotic candidate, TP-434, which is in an initial Phase II study, as well as for our next two clinical antibiotic programs, poised to enter Phase I trials ... Thu, 20 Jan 2011 08:48:00 EST http://www.tphase.com/about_us/media_events/?id=15 http://www.tphase.com/about_us/media_events/?id=2 Watertown, MA – November 11, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) Gram-negative pathogens, today announced that the Company will present at the 7th annual Lazard Capital Markets Healthcare Conference on Wednesday, November 17th , at 2:15 pm EST at the St. Regis Hotel, the Watteau room, New York and at the Piper Jaffray & Co. 22nd Annual Healthcare Conference on Wednesday, December 1st, at 1:10 pm EST at the New York Palace Hotel in New York. At both conferences,Guy Macdonald, President and CEO of Tetraphase, will provide an overview of the Company, its strategic objectives and review its pipeline, including its lead candidate TP-434, a novel broad-spectrum intravenous (I.V.) antibiotic with potential for oral step-down capable of treating multidrug-resistant Gr... Fri, 01 Jan 2010 07:58:00 EST http://www.tphase.com/about_us/media_events/?id=2 http://www.tphase.com/about_us/media_events/?id=1 – Bohlin to provide strategic leadership to optimally leverage the company’s full range of corporate development opportunities – Watertown, MA – October 12, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) Gram-negative pathogens, today announced that it has appointed Garen Bohlin to its Board of Directors, effective immediately.Mr. Bohlin will provide strategic leadership with the board, working closely with management as the Company seeks to advance its a market-leading antibiotics franchise. "Garen is renowned for building value for innovative biotechnology companies and then successfully leveraging that value to achieve an optimal outcome," said Guy Macdonald, Chief Executive Officer of Tetraphase. "With his experience and knowle... Fri, 01 Jan 2010 07:54:00 EST http://www.tphase.com/about_us/media_events/?id=1 http://www.tphase.com/about_us/media_events/?id=3 Watertown, MA – October 1, 2010 –Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) Gram-negative pathogens, today announced that the Company will present at the 9th annual BIO Investor Forum on Tuesday, October 5, at 9:00 am PT at the Palace Hotel, Pacific Heights room, San Francisco and participate in a panel discussion at Citi's 5th Annual Biotech Day on Tuesday, October 5, from 2:00pm to 3:00 pm ET at the Westin Waterfront Hotel in Boston. At the 9th BIO Investor Forum,Guy Macdonald, President and CEO of Tetraphase, will provide an overview of the Company, its strategic objectives and review its pipeline, including its lead candidate TP-434, a novel broad-spectrum intravenous (I.V.) antibiotic with potential for oral step-down capable of treating multidrug-resistant Gram-negative... Fri, 01 Oct 2010 08:04:00 EST http://www.tphase.com/about_us/media_events/?id=3 http://www.tphase.com/about_us/media_events/?id=4 Watertown, MA – September 16, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative pathogens, today announced that the Company will present at the UBS Global Life Science Conference on Monday, September 20, at 9:30 am ET at the Grand Hyatt Hotel, New York City. Guy Macdonald, President and CEO of Tetraphase, will provide an overview of the Company, its strategic objectives and review its pipeline, including its lead candidate TP-434, a novel broad-spectrum intravenous (I.V.) antibiotic with potential for oral step-down capable of treating multidrug-resistant Gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug-resistant Gram-positive, anaerobic and atypical pathogens. A live audio webcast of this ... Thu, 16 Sep 2010 08:04:00 EST http://www.tphase.com/about_us/media_events/?id=4 http://www.tphase.com/about_us/media_events/?id=6 Watertown, MA –  September 15, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative pathogens, announced that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the most promising biotech companies in the industry. An internationally recognized daily newsletter reaching more than 75,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position. “The desperate need for new antibiotics is an issue that’s rais... Wed, 15 Sep 2010 08:25:00 EST http://www.tphase.com/about_us/media_events/?id=6 http://www.tphase.com/about_us/media_events/?id=14 Presentations at 2010 ICAAC Include Data on Company’s Lead Antibiotic, TP-434, and Other Drug Candidates from Ground-breaking Chemistry Platform Watertown, MA – September 15, 2010 – Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens. The data supported the utility of TP-434 as a once daily monotherapy for serious infections. Data on TP-434, as well as data for another drug candidate, TP-271, from Tetraphase’s antibiotics product portfolio, were presented in 10 poster presentations at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) annual meeting in Boston, MA, being held September 12 -15. Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and... Wed, 15 Sep 2010 08:31:00 EST http://www.tphase.com/about_us/media_events/?id=14 http://www.tphase.com/about_us/media_events/?id=13 Data Shows TP-434 Has Potential as First-line, Broad-spectrum Antibiotic for Treatment of Gram-negative and Multidrug-resistant Infections Additional Data Shows TP-434 as an Orally Effective Antibiotic Watertown, MA – September 13, 2010 –Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once-daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant Gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug-resistant Gram-positive pathogens. Additionally, Tetraphase presented new data that showed the potential for TP-434 to be effective in an oral formulation, which makes TP-434 ideally suited as a first-line IV antibiotic with oral step-down for severe and life-threatening bacterial infections. These data were presented in an oral session and in two poster sessions at the 2010 Inter... Mon, 13 Sep 2010 08:29:00 EST http://www.tphase.com/about_us/media_events/?id=13 http://www.tphase.com/about_us/media_events/?id=12 -Includes Oral Presentation and 12 posters- Watertown, MA – September 8, 2010 – Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Convention and Exhibition Center. Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics. “We are looking forward to sharing our data with clinicians and colleagues from around the world in 13 separate data presentations, ranging from bench to clinic,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “As demonstrated by the breadth of our TP-434 data at ICAAC, we believe that TP-43... Wed, 08 Sep 2010 08:22:00 EST http://www.tphase.com/about_us/media_events/?id=12 http://www.tphase.com/about_us/media_events/?id=11 Watertown, MA – June 1, 2010 – Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing. Excel Venture Management led the round with participation from existing investors CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures. Proceeds from the Series C financing will be used to advance Tetraphase’s pipeline of novel antibiotics, into Phase 1 and Phase 2 clinical studies. The company’s lead product candidate, TP-434, a broad spectrum intravenous (IV) antibiotic with the potential for superior potency against Gram- negative pathogens is anticipated to enter Phase 2 clinical studies in 2010. In addition, the Company will advance two novel IV/oral antibiotics, TP-2758, which is designed to treat complicated urinary tr... Tue, 01 Jun 2010 08:20:00 EST http://www.tphase.com/about_us/media_events/?id=11 http://www.tphase.com/about_us/media_events/?id=10 Watertown, MA – April 29, 2010 – Tetraphase Pharmaceuticals Inc., a biopharmaceutical company developing novel antibiotics based on proprietary synthetic chemistry technology, today announced that it will be participating in a session on drug discovery and development of novel treatments for drug-resistant infections, taking place at the 2010 BIO International Convention in Chicago. On Wednesday, May 5 at 8:00 a.m., Joyce Sutcliffe, Ph.D., senior vice president, Biology at Tetraphase Pharmaceuticals, will be making a presentation during a Session entitled "Where Are the Drugs to Stop Bad Bugs?" in Room S401-AB at the McCormick Place convention center. Dr. Sutcliffe will be among speakers who will discuss new drugs in development to combat drug-resistant infections, many of which are fatal and continue to grow in number and severity. The session will focus on novel approaches to creating important new and powerful antibacterial agents, including Tetraphase’... Thu, 29 Apr 2010 08:17:00 EST http://www.tphase.com/about_us/media_events/?id=10 http://www.tphase.com/about_us/media_events/?id=9 Raises $10M to close first tranche of $25M Financing Watertown, MA –  October 06, 2009 – Tetraphase Pharmaceuticals Inc. announced today that it has closed the first tranche of its $25 million Series B financing to support the advancement of several novel and potent antibiotic drug candidates. This Series B Financing and first tranche of $10 million was funded by existing investors – Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.   Tetraphase Pharmaceuticals was established in August 2006 to advance and commercialize the ground-breaking synthetic chemistry platform developed by internationally recognized chemist, Dr. Andrew Myers of Harvard University. This proprietary platform overcomes a key barrier to discovering unprecedented classes of antibiotics and other drugs by enabling for the first time their total synthesis from basic building blocks. The initial focus of the company is ... Tue, 06 Oct 2009 08:14:00 EST http://www.tphase.com/about_us/media_events/?id=9 http://www.tphase.com/about_us/media_events/?id=8 Watertown, MA –  September 10, 2009 –  Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. “We appreciate the opportunity to share some of the results from our work with this very powerful and ground-breaking chemistry platform,” stated Mr. Guy Macdonald, President and CEO of Tetraphase Pharmaceuticals. “This enabling chemistry technology dramatically expands the chemical diversity of tetracyclines and is highly versatile, providing compounds with possibilities for IV and oral dosing routes and activity against multiple drug-resistant strains.&r... Thu, 10 Sep 2009 08:11:00 EST http://www.tphase.com/about_us/media_events/?id=8 http://www.tphase.com/about_us/media_events/?id=7 Watertown, MA – August 6, 2008 –  Tetraphase Pharmaceuticals Inc. announced today that it has closed the second tranche of its $25 million Series A financing to support the advancement of several novel and potent antibiotic drug candidates. This second tranche of $15 million was funded by existing investors – Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures. Tetraphase Pharmaceuticals was established in August 2006 to advance and commercialize the ground-breaking synthetic chemistry platform developed by internationally recognized chemist, Dr. Andrew Myers of Harvard University. This proprietary platform overcomes a key barrier to discovering unprecedented classes of antibiotics and other drugs by enabling for the first time their total synthesis from basic building blocks.  The initial focus of the company is on the discovery of novel antibiotics to treat drug-resistant infections. &nbsp... Wed, 06 Aug 2008 08:06:00 EST http://www.tphase.com/about_us/media_events/?id=7 http://www.tphase.com/about_us/media_events/?id=5 Harvard University Office of Technology Development Watertown and Cambridge, MA – November 24, 2006 –  Tetraphase Pharmaceuticals Inc. and Harvard University’s Office of Technology Development (OTD) announced today the formation of a biotechnology company that will develop new classes of antibiotics aimed at drug-resistant infections.  The Company’s approach capitalizes on ground-breaking technology and patents licensed from Harvard University.  The Company recently completed a successful $25.0 million Series A financing. The Series A round was funded by Mediphase Venture Partners, Fidelity Biosciences, Skyline Ventures, Flagship Ventures, and CMEA Ventures.  Joining the board are Lawrence Miller, MD, Mediphase Venture Partners (chairman of Tetraphase), Jason P. Rhodes, Fidelity Biosciences, Eric M. Gordon, Ph.D., Skyline Ventures, Doug Cole, MD, Flagship Ventures and Karl D. Handelsman, CMEA Ventures. Tetraphase’s... Fri, 24 Nov 2006 08:01:00 EST http://www.tphase.com/about_us/media_events/?id=5